Disappointing results in Alzheimer’s clinical trials seem to be announced on an almost monthly, and sometimes weekly basis:
- Merck’s verubecestat
- vTv’s azeliragon
- Lilly’s solanezumab
Unfortunately, these are just a few examples…there are many more.
This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC.